Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 1 · below the Ichimoku cloud · RSI 40 · MACD below its signal
None of the 29 investors followed here reported a position in RVXCF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No insider transactions reported for RVXCF.
No member of Congress has disclosed a RVXCF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 14.3 | 12.5 | -11.1 | 0.0 | -12.5 | 0.0 | 0.0 | 0.0 | 0.0 | -14.3 | −14.3% | ||
| 2025 | -25.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | 33.3 | -12.5 | 0.0 | 14.3 | -12.5 | +75.0% |
| 2024 | 0.0 | 0.0 | -20.0 | 0.0 | -25.0 | 33.3 | 25.0 | 20.0 | -33.3 | 0.0 | 0.0 | 0.0 | −20.0% |
| 2023 | 0.0 | 10.0 | -9.1 | 10.0 | -27.3 | -25.0 | 33.3 | -25.0 | -16.7 | 0.0 | 0.0 | 0.0 | −50.0% |
| 2022 | 45.0 | -13.8 | -24.0 | -21.1 | -33.3 | -5.0 | 26.3 | -16.7 | -35.0 | 0.0 | 0.0 | -23.1 | −75.0% |
| 2021 | 0.0 | 2.7 | -9.3 | 7.4 | 4.1 | -10.5 | -20.6 | -18.5 | -6.8 | 12.2 | -21.7 | 11.1 | −45.2% |
| 2020 | -4.3 | 11.2 | -34.3 | -7.7 | -5.0 | 5.3 | -3.3 | 6.9 | 56.5 | -20.6 | 2.6 | -7.6 | −21.5% |
| 2019 | 3.9 | -1.7 | 6.7 | 17.3 | -6.4 | -15.4 | -5.1 | -2.7 | -76.1 | 67.3 | 13.8 | -6.1 | −60.1% |
| 2018 | -4.2 | -8.8 | -6.9 | -25.9 | -11.0 | 105.6 | 8.7 | 20.6 | 6.2 | -1.6 | -0.8 | -6.4 | +40.4% |
| 2017 | 24.4 | -3.2 | 6.5 | -11.0 | 6.9 | -29.0 | 6.4 | -5.1 | 7.2 | -16.0 | 15.0 | 44.3 | +30.7% |
| 2016 | -5.7 | -10.3 | -3.8 | 16.0 | -16.4 | -9.3 | 2.3 | 4.4 | 60.6 | -4.0 | -9.0 | -3.8 | +3.3% |
| 2015 | 16.3 | 28.0 | 90.6 | 85.2 | -14.6 | -11.4 | -18.1 | -10.7 | 9.6 | -8.8 | 9.6 | -10.2 | +186.0% |
| 2014 | 60.9 | -8.1 | 0.0 | -7.4 | 7.9 | 8.8 | -2.7 | -5.6 | -16.2 | -1.8 | -12.5 | -12.2 | −6.5% |
| 2013 | 67.3 | -7.1 | 7.7 | 26.3 | 4.5 | -93.7 | 150.0 | 21.8 | -13.4 | -10.3 | 0.0 | -11.5 | −71.1% |
| 2012 | 12.7 | 21.9 | -2.7 | -13.4 | -12.9 | 33.3 | -12.8 | 13.4 | 10.1 | 5.1 | -10.2 | -14.1 | +18.7% |
| 2011 | -17.4 | -7.7 | 16.6 | -10.7 | 0.0 | -22.9 | 0.6 | -8.3 | -20.3 | 4.4 | -2.5 | 15.5 | −47.0% |
| 2010 | 9.0 | 17.3 | 121.1 | -11.8 | -34.0 | -35.3 | 6.4 | -6.0 | 57.4 | 33.9 | -37.1 | -23.3 | +8.1% |
| 2009 | 12.2 | -11.3 | 5.7 | -4.3 | 6.5 | -22.1 | 48.3 | -26.0 | 17.8 | -11.7 | −4.5% |
No analyst coverage for this instrument.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.